Ionis Pharmaceuticals, Inc.
Every calculator, already run for IONS
Open the full toolkit →You have the numbers on IONS. Get the argument.
A written report on which of these readings actually decide the outcome for Ionis Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
23 analysts covering IONSAnalyst Price Target Disagreement for Ionis Pharmaceuticals, Inc.
Wall Street's bull case implies +141% from the current price; the bear case implies +24%. A 117% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for IONS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment…
IONS — frequently asked
Is IONS a buy right now?
Wall Street's consensus rating on Ionis Pharmaceuticals, Inc. is Buy across 23 analysts, with a mean price target of $83.64 (+92% vs. the current $43.54). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is IONS's next earnings date?
Ionis Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 4, 2026. A full IONS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Ionis Pharmaceuticals, Inc.?
Analysts covering Ionis Pharmaceuticals, Inc. (IONS) range from a bear-case target of $54.00 to a bull-case high of $105.00, with a mean consensus target of $83.64 across 22 analysts. The spread of $51.00 (117% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Ionis Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Ionis Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full IONS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Ionis Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.